Growth equity firm General Atlantic has invested an undisclosed amount in Synaptive Medical, a Canada-based medical device and technology company.
Synaptive Medical, which was established in 2012, develops technologies which solve challenges in hospitals, particularly in operation rooms.
The company developed a suite of products which offer visual and information tools which help surgeons focus more on patient outcomes.
Synaptive’s surgical technology is a combination of informatics, imaging, surgical planning, navigation and advanced optics. These technologies are being employed in some of the top-notch health care facilities across the US.
Some of Synaptive’s recent medical and surgical installations include Emory University Hospital, the Gates Vascular Institute, Grady Health, Indiana University Health Methodist Hospital and Mount Sinai.
It had also partnered with Henry Ford Health System as an initiative to develop ONConnect, virtual tumour board, whose aim is to offer patients greater transparency in determining their options for brain tumour treatment.
Synaptive Medical president Cameron Piron said: "The healthcare industry is shifting toward an integrated delivery model that treats the whole patient from the diagnosis to surgery and beyond. Efficient medical imaging, combined with timely and effective care, is a critical driver of that change.
“Synaptive is developing novel imaging solutions that will help improve clinical outcomes for patients in partnership with the people and institutions that care for them.
"Partnering with an outstanding investor such as General Atlantic demonstrates our commitment to long-term growth.”
Right from 2014, the company has been receiving approvals for its complex surgical navigation and visualisation systems from the United States Food and Drug Administration (USFDA) and Health Canada. In four years, the company had introduced five Class-II and three Class-I medical devices in US and same number of products in Canada.
General Atlantic principal David Caluori will be joining as one of the board of directors in Synaptive.
David Caluori said: "We are excited to partner with Synaptive's passionate team, whose commitment to innovation, engagement with surgeons, and passion for patient care, has built an incredibly unique suite of products.
"Synaptive's vision for a better approach to surgery is highly disruptive and is expected to address pain points common to many surgical areas that we expect will enhance patient outcomes over time."